SciSparc shares are trading higher after the company announced it submitted an IND application to the FDA for its Phase IIb trial of SCI-110 for tourette syndrome treatment.
Portfolio Pulse from Benzinga Newsdesk
SciSparc shares rose following the submission of an IND application to the FDA for a Phase IIb trial of SCI-110, aimed at treating Tourette syndrome.
September 18, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SciSparc's stock price increased after the company submitted an IND application to the FDA for a Phase IIb trial of SCI-110, targeting Tourette syndrome treatment.
The submission of an IND application to the FDA is a significant step in drug development, indicating progress in SciSparc's clinical trials. This positive development likely boosted investor confidence, leading to a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100